葛兰素史克

GSK R&D is rapidly expanding its footprint in North/East Asia, and GSK is committed to the discovery and development of new therapies that leverage patient-driven science to deliver improved outcomes for more patients.  
As part of this strategy, CPMS is in a unique position to enable simultaneous global drug development via early ethnopharmacology assessment and deployment of Model Informed Drug Discovery and Development MID3.  In recognition of the importance of developing unifying strategies and having a pan regional influence within the evolving regulatory landscape a CPMS Asian hub organisation has been established.  
A key goal for the hub is to enable early alignment of Asia strategy with global strategy to enable global development.  This involves the optimal integration of Asia-wide CPMS expertise whilst maintaining local specialist knowledge in support of local submissions and markets. 
The hub is accountable and for defining, coordinating and defending Clinical Pharmacology Modelling & Simulation (CPMS) development strategies for North/East Asian countries, and providing expert input into the clinical pharmacology evidence generation and integrated evidence plans for key therapeutic areas (oncology, immunology, respiratory and specialty, global health and ViiV).

Want to apply your unique spectrum of skills within a single integrated global clinical pharmacology M&S discipline and be ambitious for patients? 
Please contact Dr Xuan Zhou (xuan.2.zhou@gsk.com) or Dr Scott Marshall (scott.f.marshall@gsk.com)